Cita APA (7a ed.)
Bojić, Z., Marković, F., & Kontić, M. (2026). Clinical Outcomes and Immune-Related Adverse Events in Metastatic Non-Squamous NSCLC Treated with First-Line Pembrolizumab–Chemotherapy: A Real-World Study from Serbia. Current Oncology, 33(5), 267-281.
Cita Chicago Style (17a ed.)
Bojić, Zlatan, Filip Marković, y Milica Kontić. "Clinical Outcomes and Immune-Related Adverse Events in Metastatic Non-Squamous NSCLC Treated with First-Line Pembrolizumab–Chemotherapy: A Real-World Study from Serbia." Current Oncology 33, no. 5 (2026): 267-281.
Cita MLA (9a ed.)
Bojić, Zlatan, et al. "Clinical Outcomes and Immune-Related Adverse Events in Metastatic Non-Squamous NSCLC Treated with First-Line Pembrolizumab–Chemotherapy: A Real-World Study from Serbia." Current Oncology, vol. 33, no. 5, 2026, pp. 267-281.
Precaución: Estas citas no son 100% exactas.